MICHAEL STEVEN KOPRESKI
Medical Practice in Long Valley, NJ
License number
Pennsylvania MD043349E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Long Valley, NJ 07853
Pennsylvania
Pennsylvania
Personal information
See more information about MICHAEL STEVEN KOPRESKI at radaris.comName
Address
Phone
23 Wellington Dr, Long Valley, NJ 07853
Professional information
See more information about MICHAEL STEVEN KOPRESKI at trustoria.com
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum Using Nucleic Acid Amplification Assays
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum Using Nucleic Acid Amplification Assays
US Patent:
6939675, Sep 6, 2005
Filed:
Nov 18, 2002
Appl. No.:
10/298816
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Floyd A. Benko - Palmyra PA, US
Michael S. Kopreski - Long Valley NJ, US
Floyd A. Benko - Palmyra PA, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q001/68, C12P019/34
US Classification:
435 6, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease.
Evaluation Of Diseases And Conditions Associated With Translocated Genes Using Plasma Or Serum Dna
Evaluation Of Diseases And Conditions Associated With Translocated Genes Using Plasma Or Serum Dna
US Patent:
7790395, Sep 7, 2010
Filed:
Aug 3, 2009
Appl. No.:
12/534578
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Michael S. Kopreski - Long Valley NJ, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 911, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.
Methods For Selecting Cancer Vaccine Therapies Using Extracellular Dna
Methods For Selecting Cancer Vaccine Therapies Using Extracellular Dna
US Patent:
7569350, Aug 4, 2009
Filed:
Apr 24, 2007
Appl. No.:
11/739494
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Floyd A. Benko - Palmyra PA, US
Michael S. Kopreski - Long Valley NJ, US
Floyd A. Benko - Palmyra PA, US
Assignee:
The Penn State University - University Park PA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease.
Endothermic Bandage With Dispenser For The Treatment Of Burns And Other Injuries
Endothermic Bandage With Dispenser For The Treatment Of Burns And Other Injuries
US Patent:
7588548, Sep 15, 2009
Filed:
Apr 13, 2006
Appl. No.:
11/403338
Inventors:
Michael C. Kopreski - Long Valley NJ, US
International Classification:
A61F 13/00
US Classification:
602 2, 206441, 607 96, 607112
Abstract:
This invention provides methods of treating thermal burns, chemical burns, and other injuries by a bandage within which is activated an endothermic chemical reaction upon withdrawal of the bandage from a dispenser. The endothermic bandage thereby provides a cooling treatment effect for a burn or injury. The easily portable dispenser contains an endothermic bandage that can be cut or separated in varying size, dependent upon the size and extent of the burn or injury.
Analysis Of Apoptotic Bodies In Bodily Fluids
Analysis Of Apoptotic Bodies In Bodily Fluids
US Patent:
2005026, Dec 1, 2005
Filed:
Mar 10, 2003
Appl. No.:
10/506703
Inventors:
Michael Kopreski - Long Valley NJ, US
International Classification:
C12Q001/68, C07H021/04
US Classification:
435006000, 536025400
Abstract:
This invention provides reagents and methods for detecting apoptotic bodies in bodily fluid, including blood, blood plasma, and serum. The invention provides methods for labeling apoptotic bodies and protein, nucleic acid, and phospholipids components thereof. The invention further provides methods for extracting, isolating or separating apoptotic bodies from fractions of the bodily fluid.
Comparative Analysis Of Extracellular Rna Species
Comparative Analysis Of Extracellular Rna Species
US Patent:
8163524, Apr 24, 2012
Filed:
Sep 18, 2007
Appl. No.:
11/857414
Inventors:
Michael S. Kopreski - Long Valley NJ, US
Assignee:
OncoMedx, Inc. - Long Valley NJ
International Classification:
C12P 19/34, C12Q 1/68, C07H 21/02, C07H 21/04, C07H 21/00
US Classification:
435 912, 435 61, 435 612, 435 911, 536 231, 536 243, 536 2433, 536 253
Abstract:
The invention provides methods for detecting tumor-associated RNA in plasma, serum, and other bodily fluids. In particular, the invention provides methods for detecting translocated gene RNA, including fusion gene RNA, in plasma or serum or other bodily fluids.
Method For Detection Of 5T4 Rna In Plasma Or Serum
Method For Detection Of 5T4 Rna In Plasma Or Serum
US Patent:
2005026, Nov 24, 2005
Filed:
Jul 8, 2003
Appl. No.:
10/616210
Inventors:
Michael Kopreski - Long Valley NJ, US
Christopher Gocke - Ellicott MD, US
Christopher Gocke - Ellicott MD, US
International Classification:
C12Q001/68, C07H021/04, C12P019/34
US Classification:
435006000, 536024300, 435091200
Abstract:
This invention relates to methods of detecting or inferring the presence of malignant or premalignant cells in a human that express 5T4. Provided are methods for detecting 5T4 RNA in blood, plasma, serum, other bodily fluids, cells, and tissues. The invention thereby provides an aid for the detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease.
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum
US Patent:
8048629, Nov 1, 2011
Filed:
Aug 7, 2007
Appl. No.:
11/835398
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Michael S. Kopreski - Long Valley NJ, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q 1/68, C12P 19/34, A61K 48/00
US Classification:
435 612, 435 912, 514 44
Abstract:
This invention relates to detection of specific extracellular DNA in plasma or serum fractions of human or animal blood associated with neoplastic, pre-malignant or proliferative disease. Specifically, the invention relates to detection tumor-associated DNA, and to those methods of detecting and monitoring tumor-associated DNA found in the plasma or serum fraction of blood by using DNA extraction and amplification with or without enrichment for DNA. The invention allows the selection and monitoring of patients for various cancer therapies including receptor tyrosine kinase inhibitor therapies.
Method For Detection Of Dna Methyltransferase Rna In Plasma And Serum
Method For Detection Of Dna Methyltransferase Rna In Plasma And Serum
US Patent:
2008028, Nov 20, 2008
Filed:
Apr 4, 2008
Appl. No.:
12/062879
Inventors:
Michael S. Kopreski - Long Valley NJ, US
Assignee:
ONCOMEDX, INC. - Long Valley NJ
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The methods of the invention detect in a qualitative or quantitative fashion DNA methyltransferase RNA in blood plasma, serum, and other bodily fluids. The inventive methods are useful for aiding detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease, and for identifying individuals who have a predisposition to disease or who might benefit from further evaluation, monitoring or therapy.
Analysis Of Extracellular Rna
Analysis Of Extracellular Rna
US Patent:
2009013, May 28, 2009
Filed:
Sep 17, 2008
Appl. No.:
12/212640
Inventors:
Michael S. Kopreski - Long Valley NJ, US
Assignee:
OncoMEDx, Inc. - Long Valley NJ
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 912
Abstract:
The invention provides methods for detecting tumor-associated RNA in plasma, serum, and other bodily fluids. In particular, the invention provides methods for detecting translocated gene RNA, including fusion gene RNA, in plasma or serum or other bodily fluids.